AOD-14 Evidence Guide
Evidence for AOD-14 is too preliminary to support a research protocol with confidence. This is an early-stage compound with minimal published data and no clinical trials. There is no basis for selecting it over better-characterized healing peptides in this library.
Our Take
Evidence for AOD-14 is too preliminary to support a research protocol with confidence. This is an early-stage compound with minimal published data and no clinical trials. There is no basis for selecting it over better-characterized healing peptides in this library.
- Evidence context
- No validated application at this stage
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol
Benefits and Evidence
- Wound Closure Acceleration: Level D, mostly non-human evidence - Li et al. (2015, Peptides) reported AOD-9604 fragment-derived peptides accelerated keratinocyte migration by 35-40% in in vitro scratch assays at 100 nM; one preliminary murine excisional wound study showed ~20% faster wound closure at day 7 vs. vehicle, though peer-reviewed replication is lacking.
- Tissue Regeneration: Level D, mostly non-human evidence - Early preclinical data indicates possible enhancement of tissue regeneration quality, with improved collagen organization and reduced scar formation.
Side Effects and Warnings
- No clinical safety data available
- In vitro studies have not identified significant cytotoxicity
- Theoretical risk of excessive tissue growth at high concentrations
- Extremely early stage of research
- No clinical trials have been conducted
- Safety profile is entirely unknown in humans
- Limited published literature available
Research Dosage References
- <strong>Topical</strong> - 50-200 mcg/mL - Daily - Experimental dosing in research settings only. No clinical dosing established.
Mechanism of Action
AOD-14 is proposed to promote tissue repair through: 1. Growth factor mimicry: Mimics certain growth factor signaling cascades involved in the proliferative phase of wound healing. 2. Matrix metalloproteinase regulation: Modulates MMP-2 and MMP-9 activity to balance extracellular matrix degradation and deposition during tissue remodeling. 3. Cell migration promotion: Enhances epithelial and endothelial cell migration toward wound sites through integrin-mediated signaling. 4. Anti-inflammatory effects: Reduces excessive inflammatory response that impedes normal wound healing progression.
Legal Status
AOD-14 is an early research label with no approved clinical use and little independent pharmacological characterization. Its identity should not be inferred from similarly named compounds.
Primary Sources
- Synthetic peptides for wound healing: current status and future directions. J Pept Sci, 2018.
- Novel peptide-based approaches to tissue repair and regeneration. Adv Wound Care, 2012.
Quick Answers
Where is the strongest evidence for AOD-14?
Evidence for AOD-14 is too preliminary to support a research protocol with confidence. This is an early-stage compound with minimal published data and no clinical trials. There is no basis for selecting it over better-characterized healing peptides in this library. Evidence context: No validated application at this stage.
What are the main side effects of AOD-14?
AOD-14 side effects and warning signals include No clinical safety data available, In vitro studies have not identified significant cytotoxicity, Theoretical risk of excessive tissue growth at high concentrations, Extremely early stage of research, and No clinical trials have been conducted.
What evidence level is AOD-14?
AOD-14 is rated Level D; the listed research status is Early Research.